Puma Biotechnology's (NASDAQ:PBYI) Strong Earnings Are Of Good Quality
H.C. Wainwright Maintains Puma Biotechnology(PBYI.US) With Buy Rating, Maintains Target Price $7
Buy Rating Reiterated for Puma Biotechnology Amid Promising Phase 2 Trial and Strategic FDA Engagement
Puma Biotechnology Launches Mid-Stage Trial of Alisertib to Treat Breast Cancer
Express News | Puma Biotechnology Announces Initiation of Alisca™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, Her2-Negative Metastatic Breast Cancer
Puma Biotechnology, Inc. Just Beat EPS By 23%: Here's What Analysts Think Will Happen Next